Today we shared new positive results from our Phase 2a study of patients with obesity-related heart failure with preserved ejection fraction (#HFpEF) during #HFSA2024. Learn more about the findings here: https://bit.ly/3XOkBdG
About us
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). For more information please visit https://www.rivuspharma.com/
- Website
-
https://www.rivuspharma.com/
External link for Rivus Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at Rivus Pharmaceuticals
Updates
-
We’re looking forward to the Heart Failure Society of America Annual Scientific Meeting 2024, where we’re presenting late-breaking data from our Phase 2a HuMAIN trial of our investigational controlled metabolic accelerator for heart failure with preserved ejection fraction (#HFpEF), which met the primary endpoint of weight loss in patients with obesity-related heart failure. Learn more: https://bit.ly/3Xvb6jk
-
We're #hiring a new Group Lead, Analytical Chemistry and QC – Small Molecules in Charlottesville, Virginia. Apply today or share this post with your network.
-
We’re pleased to welcome Tom O'Neil as CFO and Erin Lavelle to our Board of Directors. Their extensive industry experience will help our company drive its next phase of growth as we advance our first-in-class investigational treatment for cardiometabolic diseases including obesity-related #HeartFailure and metabolic dysfunction-associated steatohepatitis #MASH. Read more: https://bit.ly/3MF4JoA
Corporate-News-Release_final.pdf
rivuspharma.com
-
We're #hiring a new Associate Director, Analytical CMC – Small Molecules in Charlottesville, Virginia. Apply today or share this post with your network.
-
Our Phase 2a HuMAIN trial met the primary endpoint of weight reduction in patients w/ obesity-related heart failure. We're sharing detailed results highlighting our investigational therapy's potential to be the first disease-modifying #HFpEF treatment by enabling fat-specific weight loss while preserving muscle at this year's #HFSA Annual Scientific Meeting. Read more: https://bit.ly/4fArk2O
HuMAIN-Topline-Release_final.pdf
rivuspharma.com
-
We're #hiring a new Senior Director / VP, Quality - GMP & GCP in San Francisco Bay Area. Apply today or share this post with your network.
-
Reductions in muscle mass pose a persistent challenge with current weight loss medicines. Our CEO Dr. Jayson Dallas and CSO Dr. Shaharyar Khan share how our approach, which increases energy expenditure by leveraging a process called mitochondrial uncoupling, could lead to fat-specific weight loss & improvements in cardiometabolic health. Read more at BioSpace: bit.ly/3zxWwzr
-
Our investigational Controlled Metabolic Accelerator increases metabolism and reduces body fat, which is pivotal to the development of #HFpEF. The rationale and design of our Phase 2a clinical trial in HFpEF are now published in European Society of Cardiology. Learn more: bit.ly/3VZWcBW.
-
Obesity and other metabolic diseases are major risk factors for #MASH. This Global Fatty Liver Day, we're joining the community in raising awareness about this progressive liver disease and the urgent need to expand treatment options for patients. Learn more about our approach to treating metabolic diseases: rivuspharma.com